A carregar...
A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis
BACKGROUND: Rituximab (RTX) and ocrelizumab (OCR) are two anti-CD20 biologics used in MS; however, comparisons on safety and efficacy are rare. OBJECTIVE: To compare treatment outcomes over the first year with RTX and OCR. METHODS: Retrospective cohort study comprising MS patients initiating RTX at...
Na minha lista:
| Publicado no: | Mult Scler J Exp Transl Clin |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7556182/ https://ncbi.nlm.nih.gov/pubmed/33110619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217320964505 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|